1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double- blind placebo-controlled trial

被引:14
|
作者
Bolhuis, Thomas E. [1 ,2 ]
Marsman, Diane E. [1 ]
den Broeder, Alfons A. [1 ,3 ]
den Broeder, Nathan [1 ,2 ]
van der Maas, Aatke [1 ,4 ]
机构
[1] Sint Maartensklin, Dept Rheumatol, Ubbergen, Netherlands
[2] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Med Ctr, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Dept Rheumatol, Med Ctr, Nijmegen, Netherlands
[4] Sint Maartensklin, Dept Rheumatol, NL-6574 NA Ubbergen, Netherlands
来源
LANCET RHEUMATOLOGY | 2023年 / 5卷 / 04期
关键词
GIANT-CELL ARTERITIS; ACTIVITY SCORE; RHEUMATISM/AMERICAN COLLEGE; GLUCOCORTICOID TREATMENT; EUROPEAN LEAGUE; ADVERSE EVENTS; DISEASE; OUTCOMES; STATEMENT;
D O I
10.1016/S2665-9913(23)00032-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Rituximab was effective for patients with polymyalgia rheumatica in the 21-week BRIDGE-PMR randomised controlled trial. Here, we aimed to assess rates of glucocorticoid-free remission up to 1 year after infusion in an extension of this trial.Methods BRIDGE-PMR was a randomised controlled proof-of-concept trial that enrolled participants with polymyalgia rheumatica according to 2012 European League Against Rheumatism-American College of Rheumatology classification criteria at the Sint Maartenskliniek, Nijmegen, Netherlands. Patients were randomly allocated in a 1:1 ratio to receive one intravenous dose of 1000 mg rituximab or placebo, with identical pre-medication and accelerated glucocorticoid tapering over 17 weeks. After the 21-week study, patients were followed in a double-blind extension until 1 year after infusion during which standard-of-care treatment was provided. The primary outcome after 52 weeks was between-group difference in glucocorticoid-free remission (ie, polymyalgia rheumatica activity score [PMR-AS] <10), assessed in all randomly allocated participants, with data imputed using a predictive mean matching model (provided data were missing at random). A sensitivity analysis restricted to patients with complete data (complete case analysis) was also done. This trial is registered with EudraCT (2018-002641-11) and the Dutch trial database (NL7414).Findings Between Dec 18, 2019 and June 8, 2021, 47 patients enrolled in the BRIDGE-PMR were followed up in this extension study (23 [11 women and 12 men] allocated rituximab and 24 [13 women and 11 men] allocated placebo), of who 38 had recently diagnosed polymyalgia rheumatica and nine had relapsing polymyalgia rheumatica. Mean (SD) age was 64 (10) years in the rituximab group and 66 (9) years in the placebo group. All participants were White. Missing data were imputed for six participants (four rituximab, two placebo); because the data were probably missing at random, a complete case analysis was added as sensitivity analyses. In the imputed analysis, the between-group absolute difference reached statistical significance (12 [52%] of 23 in the rituximab group in glucocorticoid-free remission vs five [21%] of 24 participants in the placebo group; absolute difference 31% [95% CI 5 to 57], RR 2 center dot 5 [1 center dot 0 to 6 center dot 0]; p=0 center dot 04).In the complete case analysis, nine (47%) of 19 patients in the rituximab group were in glucocorticoid-free remission 1 year after infusion compared with five (23%) of 22 in the placebo group (absolute difference 25% [95% CI -4 to 53], relative risk (RR) 2 center dot 1 [95% CI 0 center dot 8 to 5 center dot 2]; p=0 center dot 12). Eight (33%) patients in the placebo group and six (26%) in the rituximab group had adverse events.Interpretation After a single dose of rituximab (1000 mg), the proportion of patients with polymyalgia rheumatica in glucocorticoid-free remission remained stable at 1 year after infusion, and a glucocorticoid sparing effect was evident. A larger trial including possibility for retreatment is warranted to confirm these results. Funding Sint Maartenskliniek.Copyright (c) 2023 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:e208 / e214
页数:7
相关论文
共 50 条
  • [41] No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
    Carr, A
    Workman, C
    Carey, D
    Rogers, G
    Martin, A
    Baker, D
    Wand, H
    Law, M
    Samaras, K
    Emery, S
    Cooper, DA
    LANCET, 2004, 363 (9407): : 429 - 438
  • [42] Lactitol in treatment of subclinical hepatic encephalopathy: a double-blind placebo-controlled randomised trial
    Li, HY
    Shi, H
    Fu, ZJ
    Zhu, L
    Chen, WZ
    CHINESE MEDICAL JOURNAL, 1998, 111 (02) : 135 - 135
  • [43] Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
    Perez, V
    Gilaberte, I
    Faries, D
    Alvarez, E
    Artigas, F
    LANCET, 1997, 349 (9065): : 1594 - 1597
  • [44] Guaifenesin as treatment for fibromyalgia: A 1 year double-blind, placebo-controlled study.
    不详
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 2 - 2
  • [45] Escitalopram in the Treatment of Adolescent Depression: A Randomized, Double-Blind, Placebo-Controlled Extension Trial
    Findling, Robert L.
    Robb, Adelaide
    Bose, Anjana
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2013, 23 (07) : 468 - 480
  • [46] A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome
    Jankovic, J.
    Jimenez-Shahed, J.
    Brown, L. W.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (01): : 70 - 73
  • [47] Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
    Li, Yan
    Li, Kunpeng
    Zhao, Zheng
    Wang, Yanyan
    Jin, Jingyu
    Zhang, Jianglin
    Zhu, Jian
    Huang, Feng
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3787 - 3788
  • [48] Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
    Li, Yan
    Li, Kunpeng
    Zhao, Zheng
    Wang, Yanyan
    Jin, Jingyu
    Guo, Junhua
    Zhang, Jie
    Zhang, Jianglin
    Zhu, Jian
    Huang, Feng
    FRONTIERS IN MEDICINE, 2021, 8
  • [49] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
    Astrup, Arne
    Rossner, Stephan
    Van Gaal, Luc
    Rissanen, Aila
    Niskanen, Leo
    Al Hakim, Mazin
    Madsen, Jesper
    Rasmussen, Mads F.
    Lean, Michael E. J.
    LANCET, 2009, 374 (9701): : 1606 - 1616
  • [50] A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation
    Tonnesen, P
    Tonstad, S
    Hjalmarson, A
    Lebargy, F
    van Spiegel, PI
    Hider, A
    Sweet, R
    Townsend, J
    JOURNAL OF INTERNAL MEDICINE, 2003, 254 (02) : 184 - 192